APTX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 des 2023 @ 21:59):

Stats
Dagens volum	231 126
Gjennomsnittsvolum	132 918
Markedsverdi	6.50M
EPS	$0 ( 2024-04-04 )
Neste inntjeningsdato	( $0 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0980
ATR14	$0.00400 (4.17%)

Insider Trading

Date	Person	Action	Amount	type
2023-01-03	Khanna Ashish	Buy	375 000	Stock Option (Right to Buy)
2023-01-03	Riedel Norbert G	Buy	420 000	Stock Option (Right to Buy)
2023-01-03	Kidd Andrew	Buy	700 000	Stock Option (Right to Buy)
2022-05-26	Koppel Adam	Buy	40 000	Stock Option (Right to Buy)
2022-05-26	Koppel Adam	Buy	40 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 97 transactions
Buy: 16 590 862 \| Sell: 1 518 818

Volum Korrelasjon

Lang: 0.42 (neutral)

Kort: 0.45 (neutral)

Signal:(66.425) Neutral

Aptinyx Inc Korrelasjon

10 Mest positive korrelasjoner
GNUS	0.981
UEIC	0.973
GMBL	0.966
QNRX	0.946
FAMI	0.945
BAND	0.945
JAGX	0.943
INFI	0.942
PIXY	0.94
GROM	0.938

10 Mest negative korrelasjoner
AGFS	-0.94
APEN	-0.935
LMRK	-0.889
SGEN	-0.885
KNBE	-0.884
TIG	-0.883
MYRG	-0.876
RDUS	-0.875
QADA	-0.871
IMRA	-0.862

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Aptinyx Inc Korrelasjon - Valuta/Råvare

-0.31
( neutral )

-0.11
( neutral )

0.00
( neutral )

-0.69
( moderate negative )

-0.13
( neutral )

Aptinyx Inc Økonomi

Annual	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.950

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.950

FY	2021
Omsetning:	$1.00M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$0

FY	2020
Omsetning:	$1.56M
Bruttogevinst:	$1 564.00 (0.10 %)
EPS:	$-1.020

Financial Reports:

No articles found.

Aptinyx Inc

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.